B

Researcher Profile

B. Sangro

3

Publications

343

Citations

10

Co-Authors

2

Active Years

Publications

Journal Article Annals of Oncology Jul 01, 2025

148O Overall evaluation of health-related quality of life (HRQoL) and efficacy assessment in patients (pts) who discontinued (d/c) due to treatment-related adverse events (TRAEs): Results from CheckMate 9DW

B. Sangro · T. Decaëns · P.R. Galle · M. Kudo +16 more

10.1016/j.annonc.2025.05.161 1 citations

Open Access Journal Article Annals of Oncology Jun 01, 2024

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

I. Melero · T. Yau · Y.-K. Kang · T.-Y. Kim +17 more

10.1016/j.annonc.2024.03.005 77 citations

Open Access Journal Article Annals of Oncology May 01, 2024

Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

B. Sangro · S.L. Chan · R.K. Kelley · G. Lau +198 more

10.1016/j.annonc.2024.02.005 265 citations

Publication Timeline

2025

1

2024

2

Frequent Co-Authors

Enrico N. De Toni

Yoshiyuki Takei

Dirk Waldschmidt

Crystal Denlinger